Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|January 6, 2021

The Isolation and Disconnection of Seniors

Author(s)Judith Feld, MD, MPH, MMM, DLFAPA

Social distancing and quarantine have been absolutely necessary, but what effect have they had on seniors?

Judith Feld, MD, MPH, MMM, DLFAPA, speaks to the unique and concerning issues seniors face with this pandemic.

Dr Feld is National Medical Director at Ontrak.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

long covid

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

August 31st 2026

1 expert is featured in this series.

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

ByDavid Walling, PhD

July 8th 2026

1 expert is featured in this series.

Managing Tolerability and Setting Patients Up for Success with Cobenfy

ByDavid Walling, PhD

July 1st 2026

1 expert is featured in this series.

The Switch Study: Why a New Mechanism Demands a New Approach

ByDavid Walling, PhD

June 17th 2026

dewboreas/Adobe Stock

Student Researchers Share Projects on Alzheimer Disease, Autism, and Long COVID, From the Regeneron Science Talent Search

ByJessica Walters,Jashvi Desai,Edward Kang,Leon Wang

April 21st 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Insanity Trials and The Court of Popular Opinion

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap

August 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News

International Overdose Awareness Day Marks 25th Year as US Overdose Deaths Decline Yet Remain High